Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC

Introduction: EGFR tyrosine kinase inhibitor improved the survival of patients with metastatic EGFR mutation-positive (EGFRm+) NSCLC. Despite high response rates, resistance develops inevitably in every patient. In up to 13%, HER2 protein overexpression is found on progression. We hypothesized that...

Full description

Bibliographic Details
Main Authors: M. Jebbink, MD, A.J. de Langen, MD, PhD, K. Monkhorst, MD, PhD, M.C. Boelens, PhD, D. van den Broek, PhD, V. van der Noort, PhD, C.J. de Gooijer, MD, PhD, M. Mahn, MSc, A.J. van der Wekken, MD, PhD, L. Hendriks, MD, PhD, S.M.S. Hashemi, MD, PhD, M.S. Paats, MD, PhD, A.C. Dingemans, MD, PhD, E.F. Smit, MD, PhD
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:JTO Clinical and Research Reports
Subjects:
EGFR
NSCLC
Osimertinib
Resistance
HER2
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000206

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000206

Similar Items